

Liquid Biopsy Markets: Global Analysis and Opportunity Evaluation 2016 - 2020

<https://marketpublishers.com/r/LF5C073E6DAEN.html>

Date: October 2016

Pages: 389

Price: US\$ 5,950.00 (Single User License)

ID: LF5C073E6DAEN

Abstracts

This market report gives a comprehensive and easy-to-review analysis of the liquid biopsy market 2016 – 2020. It provides key market data and identifies new and emerging opportunities relating to circulating tumour cells (CTCs) and circulating cell-free DNA and RNA (cfDNA and cfRNA). The analysis is based on primary data disclosed by experienced end-users' in the clinical, diagnostics and research fields on their current liquid biopsy practices and their plans over the next three. Its findings provide a wealth of market information on the liquid biopsy market and enables suppliers to reduce costs, identify new markets and compete more effectively in the global marketplace.

Recent years have seen the rapid development of minimally invasive diagnostic techniques in the cancer field, notably relating to so-called 'liquid biopsies'. These developments have included the study and characterisation of circulating tumour cells and (CTCs) and circulating cell-free nucleic acids (cfDNA and cfRNA). Today, around 50 companies offer techniques that image, enrich, isolate or characterise CTCs and more advanced methods are also being used to isolate and characterise cfDNA and cfRNA. Advances are also being seen in the study of CTC sub-populations, time-dependent changes and the markers used to isolate or enrich them and new methods are increasingly being applied to cfDNA and cfRNA. Both of these strategies are seeing rapid development, as researchers and developers seek to translate these methodologies and the findings they are providing, into diagnostic tests that impact on clinical care or which drive new discovery.

Nevertheless, despite the excitement these developments are creating, important and fundamental questions remain unanswered. Laboratory Markets Ltd has carried out two comprehensive studies of diagnostic developments relating to CTCs, cell-free nucleic

acids (cfDNA and cfRNA) and exosomes. These were carried out to help address these questions and to assist diagnostic companies to identify and support evolving diagnostic needs in these growing fields.

This report presents the findings of a new 'liquid biopsy' market study on CTCs, circulating cell-free nucleic acids and exosomes, completed in December 2015. These findings are analysed alongside results of a study of these markets, completed eighteen months earlier. Findings from these two studies, which present the disclosures of experienced researchers and clinicians in these fields, allowed an in-depth analysis of new developments and trends being seen in these growing diagnostic market areas.

The current studies profiled 482 experienced clinicians and research scientists, and covered CTC and cfDNA and cfRNA current practices, developments, trends and three-year plans, as well as growth, shrinkage and opportunities across key areas of these diagnostic markets. Its findings provide diagnostic companies with market information on the current and evolving use of CTCs and cfDNA and cfRNA, as well as exosomes, and the techniques that are driving these developments.

Our specialised market studies are designed to assist diagnostic companies and developers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies help companies identify qualified leads, to sell into these markets and also support innovation and strategic planning.

Companies mentioned

More than 120 companies are mentioned in this report, namely A&A Biotechnology, AB ANALITICA, Abbott, Abcam, ABI, Abnova, ABSciex, AccuGenomics, Aczon, Adnagen, Advanced Cell Diagnostics, AdvanDx, Affymetrix, Agendia, Agilent, ALS Jena, AMNIS, Amoy Diagnostics, Angle Technology, Applied Biosystems, Argene Inc (Biomerieux), Arrayit, Asuragen, Axis Shield, Axygen Products, Bayer, BD, Beckman Coulter, Becton Dickinson, Biocept, BioGenex, BioLegend, Bioline, Biometra, Bioneer, Bio-Rad, Biovendor, Bioview, Cancer Genetics, Canopus, Caris Life Sciences, Cell Search, Cell Signaling Technology, Chemicon, Clariant, Compucyte, Cynvenio, Cytocell, Dako (Agilent), Dianova, Dynam, eBiosciences, Empire Genomics, Enzo Life Sciences, Epic Sciences, Eppendorf, Eurofins, Eurogentec, Euroimmun, Falcon Genomics, Fermantas, Filtini, Fluidigm, Fluxion, Foundation Medicine, GE Healthcare, Genetix, GenMark

Diagnostics, Greiner Bio-One, IDEXX, IDT, IDVET, Ikonisys, Illumina, Interpath, Invitrogen, Invitrogen (Life Technologies), Ipsogen (Qiagen), Janssen-Veridex, Leika, Life Technologies, Luminex, Merck, MetaCell, Millipore, Miltenyi Biotech, Molecular Devices, MolecularMD, MP-Biomedicals, Myriad Genetics, Nanostring, New England Biolabs, Olink, Ortho, Oxoid, Pathology, Peqlab, Perkin Elmer, Peviva, Promega, Qiagen, R&D, Rarecells, Roche, Roche Diagnostics, Santacruz, ScreenCell, Shimadzu, Siemens, Sigma Aldrich, Silicon Systems, Stemcell Tech, StemCell Technologies, Sysmex, Takara, ThermoFisher, TiBMolBiol, Ventana (Roche), Viatar CTC Solutions, Vitatek, VWR, Zeiss and Zymo Research.

Contents

INDEX

CHAPTER 1. BACKGROUND

- 1.1. This Chapter
- 1.2. Background
- 1.3. Study Questions

CHAPTER 2. STUDY PARTICIPANTS

- 2.1. This Chapter
- 2.2. Global Regions
 - Figure 2.1. Global regions of participants in CircBio 2015
 - Table 2.1. Global regions of participants in CircBio 2015
 - Figure 2.2. Global regions of participants inCircBio 2015 (Study 1)
 - Table 2.2. Global regions of participants inCircBio 2015 (Study 1)
- 2.3. Countries
 - Figure 2.3. Top ten countries of participants in CircBio 2015
 - Table 2.3. Countries of participants in CircBio 2015
 - Figure 2.4. Top ten countries of participants inCircBio 2015 (Study 1)
 - Table 2.4. Countries of participants inCircBio 2015 (Study 1)
- 2.4. Organisation Types
 - Figure 2.5. Organisation types of participants in CircBio 2015
 - Table 2.5. Organisation types of participants in CircBio 2015
 - Figure 2.6. Organisation types of participants inCircBio 2015 (Study 1)
 - Table 2.6. Organisation types of participants inCircBio 2015 (Study 1)
- 2.5. Role
 - Figure 2.7. Roles of participants in CircBio 2015
 - Table 2.7. Roles of participants in CircBio 2015
 - Figure 2.8. Roles of participants in CircBio 2015 (Study 1)
 - Table 2.8. Roles of participants in CircBio 2015 (Study 1)
- 2.6. Experience
 - Figure 2.9. Top ten experience levels of participants in CircBio 2015
 - Table 2.9. Experience of participants in CircBio 2015
 - Figure 2.10. Top ten experience levels of participants in CircBio 2015 (Study 1)
 - Table 2.10. Experience of participants in CircBio 2015 (Study 1)
- 2.7 Discussion

CHAPTER 3. AREA OF WORK

3.1. This Chapter

3.2. Area of Work

Figure 3.1. Area of work of participants in CircBio 2015 participants

Table 3.1. Area of work of participants in CircBio 2015 participants

Figure 3.2. Area of work of participants in CircBio 2015 participants (Study 1)

Table 3.2. Area of work of participants in CircBio 2015 participants (Study 1)

CHAPTER 4. CIRCULATING TUMOUR CELLS

4.1. This Chapter

4.2. Role of Participant

Figure 4.1. Role of CircBio 2015 participants in the cancer field, who study CTCs in their work.

Table 4.1. Role of CircBio 2015 participants in the cancer field, who study CTCs in their work.

Figure 4.2. Role of CircBio 2015 participants in the cancer field, who study CTCs in their work (Study 1)

Table 4.2. Role of CircBio 2015 participants in the cancer field, who study CTCs in their work (Study 1)

4.3. Current Purposes

Figure 4.3. Top ten current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants

Table 4.3. Current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants

Figure 4.4. Top ten current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)

Table 4.4. Current main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.4. Future Purposes

Figure 4.5. Top ten future main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants

Table 4.5. Future main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants

Figure 4.6. Top ten future main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)

Table 4.6. Future main purpose(s) of their work, relating to CTCs, of CircBio 2015 participants (Study 1)

participants (Study 1)

4.5. Current Cancers

Figure 4.7. Top ten current cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants

Table 4.7. Current cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants

Figure 4.8. Top ten current cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants (Study 1)

Table 4.8. Current cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants (Study 1)

4.6. Future Cancer

Figure 4.9. Top ten future cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants

Table 4.9. Future cancers investigated in their work, relating to CTCs, of CircBio 2015 participants

Figure 4.10. Top ten future cancers investigated in their work, relating to CTCs, ofCircBio 2015 participants (Study 1)

Table 4.10. Future cancers investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.7. Current Samples

Figure 4.11. Top ten current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants

Table 4.11. Current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants

Figure 4.12. Top ten current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

Table 4.12. Current sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.8. Future Samples

Figure 4.13. Top ten future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants

Table 4.13. Future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants

Figure 4.14. Top ten future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

Table 4.14. Future sample types investigated in their work, relating to CTCs, of CircBio 2015 participants (Study 1)

4.9. Study of CTC Sub-Populations

Figure 4.15. CircBio 2015 participants' study of CTC sub-populations in their CTC work

Table 4.15. CircBio 2015 participants' study of CTC sub-populations in their CTC work
Figure 4.16. CircBio 2015 participants' study of CTC sub-populations in their CTC work
(Study 1)

Table 4.16. CircBio 2015 participants' study of CTC sub-populations in their CTC work
(Study 1)

4.10. Current CTC Sub-Populations

Figure 4.17. Top ten current CTC subpopulations studied, for those CircBio 2015 participants who answered 'yes' to the previous question

Table 4.17. Current CTC subpopulations studied, for those CircBio 2015 participants who answered 'yes' to the previous question

Figure 4.18. Top ten current CTC subpopulations studied, for those CircBio 2015 participants who answered 'yes' to the previous question (Study 1)

Table 4.18. Current CTC subpopulations studied, for those CircBio 2015 participants who answered 'yes' to the previous question (Study 1)

4.11. Future CTC Sub-Populations

Figure 4.19. Top ten future anticipated CTC subpopulations to be studied, by those CircBio 2015 participants who answered 'yes' to the previous question

Table 4.19. Future CTC subpopulations anticipated studied, by those CircBio 2015 participants who answered 'yes' to the previous question

Figure 4.20. Top ten future anticipated CTC subpopulations to be studied, by those CircBio 2015 participants who answered 'yes' to the previous question (Study 1)

Table 4.20. Future CTC subpopulations anticipated studied, by those CircBio 2015 participants who answered 'yes' to the previous question (Study 1)

4.12. Future Study of CTC Sub-Populations

Figure 4.21. The future anticipated study of CTC subpopulations, by those CircBio 2015 participants who answered 'No' to the previous question (see sections 4.10)

Table 4.21. The future anticipated study of CTC subpopulations, by those CircBio 2015 participants who answered 'No' to the previous question (see sections 4.10)

Figure 4.22. The future anticipated study of CTC subpopulations, by those CircBio 2015 participants who answered 'No' to the previous question (see sections 4.10)
(Study 1)

Table 4.22. The future anticipated study of CTC subpopulations, by those CircBio 2015 participants who answered 'No' to the previous question (see sections 4.10) (Study 1)

4.13. Current CTC Measurements

Figure 4.23. Current CTC measurements used by CircBio 2015 participants, in their CTC studies

Table 4.23. Current CTC measurements used by CircBio 2015 participants, in their CTC studies

Figure 4.24. Current CTC measurements used by CircBio 2015 participants, in their

CTC studies (Study 1)

Table 4.24. Current CTC measurements used byCircBio 2015 participants, in their CTC studies (Study 1)

4.14. Future CTC Measurements

Figure 4.25. Future anticipated CTC measurements ofCircBio 2015 participants, in their CTC studies.

Table 4.25. Future anticipated CTC measurements ofCircBio 2015 participants, in their CTC studies.

Figure 4.26. Future anticipated CTC measurements ofCircBio 2015 participants, in their CTC studies (Study 1)

Table 4.26. Future anticipated CTC measurements ofCircBio 2015 participants, in their CTC studies (Study 1)

4.15. Current CTC Markers

Figure 4.27. Top ten current CTC markers studied byCircBio 2015 participants, in their CTC studies

Table 4.27. Current CTC markers studied byCircBio 2015 participants, in their CTC studies

Figure 4.28. Top ten current CTC markers studied byCircBio 2015 participants, in their CTC studies (Study 1)

Table 4.28. Current CTC markers studied byCircBio 2015 participants, in their CTC studies (Study 1)

4.16. Future CTC Markers

Figure 4.29. Top ten future CTC markers anticipated to be studied byCircBio 2015 participants, in their CTC studies

Table 4.29. Future CTC markers anticipated to be studied byCircBio 2015 participants, in their CTC studies

Figure 4.30. Top ten future CTC markers anticipated to be studied byCircBio 2015 participants, in their CTC studies (Study 1)

Table 4.30. Future CTC markers anticipated to be studied byCircBio 2015 participants, in their CTC studies (Study 1)

4.17. Current CTC Enrichment, Isolation or Detection Methods

Figure 4.31. Top ten current CTC enrichment, isolation or detection methods used byCircBio 2015 participants, in their CTC studies

Table 4.31. Current CTC enrichment, isolation or detection methods used byCircBio 2015 participants, in their CTC studies

Figure 4.32. Top ten current CTC enrichment, isolation or detection methods used byCircBio 2015 participants, in their CTC studies (Study 1)

Table 4.32. Current CTC enrichment, isolation or detection methods used byCircBio 2015 participants, in their CTC studies (Study 1)

4.18. Current CTC Enrichment, Isolation or Detection Methods

Figure 4.33. Top ten current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies

Table 4.33. Current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies

Figure 4.34. Top ten current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

Table 4.34. Current CTC enrichment, isolation or detection methods used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.19. Future CTC Enrichment, Isolation or Detection Methods

Figure 4.35. Top ten future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies

Table 4.35. Future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies

Figure 4.36. Top ten future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

Table 4.36. Future CTC enrichment, isolation or detection methods anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.20. Current Non-Molecular Techniques

Figure 4.37. Top ten current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies

Table 4.37. Current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies

Figure 4.38. Top ten current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

Table 4.38. Current non-molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.21. Future Non-Molecular Techniques

Figure 4.39. Top ten future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies

Table 4.39. Future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies

Figure 4.40. Top ten future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

Table 4.40. Future non-molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.22. Current Molecular Techniques

Figure 4.41. Top ten current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies

Table 4.42. Current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies

Figure 4.42. Top ten current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

Table 4.42. Current molecular techniques used by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.23. Future Molecular Techniques

Figure 4.43. Top ten future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies

Table 4.43. Future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies

Figure 4.44. Top ten future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

Table 4.44. Future molecular techniques anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.24. Current Molecular Suppliers

Figure 4.45. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to

Table 4.45. Current main suppliers of molecular products (systems, kits, reagents) relating to

Figure 4.46. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)

Table 4.46. Current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)

4.25. Future Molecular Suppliers

Figure 4.47. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by

Table 4.47. Future main suppliers of molecular products (systems, kits, reagents), anticipated by

Figure 4.48. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)

Table 4.48. Future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)

4.26. Current Nucleic Acid Forms

Figure 4.49. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies

Table 4.49. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies

Figure 4.50. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants,

in their CTC studies (Study 1)

Table 4.50. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.27. Future Nucleic Acid Forms

Figure 4.51. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies

Table 4.51. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies

Figure 4.52. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

Table 4.52. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their CTC studies (Study 1)

4.28. Current CTC Molecular Biomarkers

Figure 4.53. Top ten current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies

Table 4.53. Current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies

Figure 4.54. Top ten current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)

Table 4.54. Current CTC molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)

4.29. Future CTC Molecular Biomarkers

Figure 4.55. Top ten future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies

Table 4.55. Future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies

Figure 4.56. Top ten future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)

Table 4.56. Future CTC molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their CTC studies (Study 1)

4.30. Clinical Utilities

Figure 4.57. Top ten clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015

Table 4.57. Clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015

Figure 4.58. Top ten clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)

Table 4.58. Clinical utilities of studying CTCs, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)

4.31. Recent CTC Trends

Figure 4.59. Top ten recent trends in the number of CTC tests (% increase or % decrease). Indicated by CTC cfDNA-RNA 2015 participants

Table 4.59. Recent trends in the number of CTC tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants

Figure 4.60. Top ten recent trends in the number of CTC tests (% increase or % decrease). Indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 4.60. Recent trends in the number of CTC tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.32. Future CTC Trends

Figure 4.61. Top ten future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants

Table 4.61. Future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants

Figure 4.62. Top ten future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 4.62. Future trends in the number of CTC tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

4.33. CTC Limitations

Figure 4.63. Top ten limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants

Table 4.63. Limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants

Figure 4.64. Top ten limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 4.64. Limitations in the study of CTCs, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.34. Costs

Figure 4.65. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants

Table 4.65. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants

Figure 4.66. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 4.66. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for CTC tests, indicated by CTC cfDNA-RNA 2015 participants

participants (Study 1)

4.35. CTCs in Drug R&D

Figure 4.67. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants

Table 4.67. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants

Figure 4.68. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 4.68. Use of CTCs in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.36. CTCs and Drug R&D Development Phase

Figure 4.69. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29)

Table 4.69. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29)

Figure 4.70. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29) (Study 1)

Table 4.70. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 4.29) (Study 1)

4.37. Future use of CTCs in Drug R&D

Figure 4.71. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29)

Table 4.71. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29)

Figure 4.72. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29) (Study 1)

Table 4.72. Future use of CTCs in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 4.29) (Study 1)

4.38. CTCs in Companion Diagnostics

Figure 4.73. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants

Table 4.73. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants

Figure 4.74. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 4.74. The use of CTCs in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

4.39. CTCs in Future Companion Diagnostics

Figure 4.75. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants

Table 4.75. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants

Figure 4.76. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 4.76. The future use of CTCs in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

CHAPTER 5 CIRCULATING CELL-FREE DNA AND RNA (CFDNA AND CFRNA)

5.1. This Chapter

5.2. Role of Participant

Figure 5.1. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA in their work.

Table 5.1. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA. In their work.

Figure 5.2. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA in their work (Study 1)

Table 5.2. Role of CTC cfDNA-RNA 2015 participants in the cancer field, who study cfDNA and/or cfRNA. In their work (Study 1)

5.3. Current Purpose

Figure 5.3. Participant's top ten current purposes of the study of cfDNA or cfRNA in their work.

Table 5.3. Participant's current purposes of the study of cfDNA or cfRNA in their work.

Figure 5.4. Participant's top ten current purposes of the study of cfDNA or cfRNA in their work (Study 1)

Table 5.4. Participant's current purposes of the study of cfDNA or cfRNA in their work (Study 1)

5.4. Future Purpose

Figure 5.5. The top ten future anticipated purposes of the study of cfDNA or cfRNA in their work.

Table 5.5. The future anticipated purposes of the study of cfDNA or cfRNA in their work.

Figure 5.6. The top ten future anticipated purposes of the study of cfDNA or cfRNA in their work (Study 1)

Table 5.6. The future anticipated purposes of the study of cfDNA or cfRNA in their work (Study 1)

5.5. Current Diseases

Figure 5.7. Top ten current diseases to which participant's cfDNA or cfRNA studies relate.

Table 5.7. Current diseases to which participant's cfDNA or cfRNA studies relate.

Figure 5.8. Top ten current diseases to which participant's cfDNA or cfRNA studies relate (Study 1)

Table 5.8. Current diseases to which participant's cfDNA or cfRNA studies relate (Study 1)

5.6. Future Diseases

Figure 5.9. Top ten anticipated future diseases to which participant's cfDNA or cfRNA studies relate

Table 5.9. Anticipated future diseases to which participant's cfDNA or cfRNA studies relate

Figure 5.10. Top ten anticipated future diseases to which participant's cfDNA or cfRNA studies relate (Study 1)

Table 5.10. Anticipated future diseases to which participant's cfDNA or cfRNA studies relate (Study 1)

5.7. Current Cancers

Figure 5.11. Top ten current cancers to which participant's cfDNA or cfRNA studies relate.

Table 5.11. Current cancers to which participant's cfDNA or cfRNA studies relate.

Figure 5.12. Top ten current cancers to which participant's cfDNA or cfRNA studies relate (Study 1)

Table 5.12. Current cancers to which participant's cfDNA or cfRNA studies relate (Study 1)

5.8. Future Cancers

Figure 5.13. Top ten anticipated future cancers to which participant's cfDNA or cfRNA studies relate

Table 5.13. Anticipated future cancers to which participant's cfDNA or cfRNA studies relate

Figure 5.14. Top ten anticipated future cancers to which participant's cfDNA or cfRNA studies relate (Study 1)

Table 5.14. Anticipated future cancers to which participant's cfDNA or cfRNA studies relate (Study 1)

5.9. Current Sample Types

Figure 5.15. Top ten current sample types to which participant's cfDNA or cfRNA studies relate.

Table 5.15. Current sample types to which participant's cfDNA or cfRNA studies relate.

Figure 5.16. Top ten current sample types to which participant's cfDNA or cfRNA

studies relate (Study 1)

Table 5.16. Current sample types to which participant's cfDNA or cfRNA studies relate (Study 1)

5.10. Future Sample Types

Figure 5.17. Top ten anticipated future sample types to which participant's cfDNA or cfRNA studies relate

Table 5.17. Anticipated future sample types to which participant's cfDNA or cfRNA studies relate

Figure 5.18. Top ten anticipated future sample types to which participant's cfDNA or cfRNA studies relate (Study 1)

Table 5.18. Anticipated future sample types to which participant's cfDNA or cfRNA studies relate (Study 1)

5.11. Current Molecular Techniques

Figure 5.19. Top ten current molecular techniques to which participant's cfDNA or cfRNA studies relate.

Table 5.19. Current molecular techniques to which participant's cfDNA or cfRNA studies relate

Figure 5.20. Top ten current molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)

Table 5.20. Current molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)

5.12. Future Molecular Techniques

Figure 5.21. Top ten anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate

Table 5.21. Anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate

Figure 5.22. Top ten anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)

Table 5.22. Anticipated future molecular techniques to which participant's cfDNA or cfRNA studies relate (Study 1)

5.13. Current Molecular Suppliers

Figure 5.23. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to

Table 5.23. Current main suppliers of molecular products (systems, kits, reagents) relating to

Figure 5.24. Top ten current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)

Table 5.24. Current main suppliers of molecular products (systems, kits, reagents) relating to (Study 1)

5.14. Future Molecular Suppliers

Figure 5.25. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by

Table 5.25. Future main suppliers of molecular products (systems, kits, reagents), anticipated by

Figure 5.26. Top ten future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)

Table 5.26. Future main suppliers of molecular products (systems, kits, reagents), anticipated by (Study 1)

5.15. Enrichment or Isolation

5.16. Current Nucleic Acid Forms

Figure 5.27. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies

Table 5.27. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies

Figure 5.28. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)

Table 5.28. Current nucleic acid forms studied by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)

5.17. Future Nucleic Acid Forms

Figure 5.29. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies

Table 5.29. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies

Figure 5.30. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)

Table 5.30. Future nucleic acid forms anticipated by CTC cfDNA-RNA 2015 participants, in their cfDNA and/or cfRNA studies (Study 1)

5.18. Current cfDNA and/or cfRNA Molecular Biomarkers

Figure 5.31. Top ten current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies

Table 5.31. Current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies

Figure 5.32. Top ten current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)

Table 5.32. Current cfDNA and/or cfRNA molecular biomarkers studied by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)

5.19. Future cfDNA and/or cfRNA Molecular Biomarkers

Figure 5.33. Top ten future cfDNA and/or cfRNA molecular biomarkers anticipated by

CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies

Table 5.33. Future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies

Figure 5.34. Top ten future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)

Table 5.34. Future cfDNA and/or cfRNA molecular biomarkers anticipated by CTC cfDNA-RNA 2015 participants in their cfDNA and/or cfRNA studies (Study 1)

5.20. Clinical Utilities

Figure 5.35. Top ten clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015

Table 5.35. Clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015

Figure 5.36. Top ten clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)

Table 5.36. Clinical utilities of studying cfDNA and/or cfRNA, indicated by participants in CTC cfDNA-RNA 2015 (Study 1)

5.21. Recent cfDNA and/or cfRNA Trends

Figure 5.37. Top ten recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants

Table 5.37. Recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants

Figure 5.38. Top ten recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 5.38. Recent trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.22. Future cfDNA and/or cfRNA Trends

Figure 5.39. Top ten future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants

Table 5.39. Future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants

Figure 5.40. Top ten future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 5.40. Future trends in the number of cfDNA and/or cfRNA tests (% increase or % decrease), anticipated by CTC cfDNA-RNA 2015 participants (Study 1)

5.23. cfDNA and/or cfRNA Limitations

Figure 5.41. Top ten limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants

Table 5.41. Limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants

Figure 5.42. Top ten limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 5.42. Limitations in the study of cfDNA and/or cfRNA, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.24. Costs

Figure 5.43. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants

Table 5.43. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants

Figure 5.44. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 5.44. Per-patient test costs (including replicates and controls, but excluding instrumentation and overheads) for cfDNA and/or cfRNA tests, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.25. cfDNA and/or cfRNA in Drug R&D

Figure 5.45. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants

Table 5.45. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants

Figure 5.46. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 5.46. Use of cfDNA and/or cfRNA in drug R&D, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.26. cfDNA and/or cfRNA and Drug R&D Development Phase

Figure 5.47. Use of cfDNA and/or cfRNA in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27)

Table 5.47. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27)

Figure 5.48. Use of cfDNA and/or cfRNA in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27) (Study 1)

Table 5.48. Use of CTCs in drug R&D by development phase, indicated by CTC cfDNA-RNA 2015 participants who indicated 'yes' to the previous question (see 5.27) (Study 1)

5.27. Future use of cfDNA and/or cfRNA in Drug R&D

Figure 5.49. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27)

Table 5.49. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27)

Figure 5.50. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27) (Study 1)

Table 5.50. Future use of cfDNA and/or cfRNA in drug R&D by CTC cfDNA-RNA 2015 participants who indicated 'no' to the previous related question (see section 5.27) (Study 1)

5.28. cfDNA and/or cfRNA in Companion Diagnostics

Figure 5.51. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants

Table 5.51. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants

Figure 5.52. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

Table 5.52. The use of cfDNA and/or cfRNA in the development of companion diagnostics, indicated by CTC cfDNA-RNA 2015 participants (Study 1)

5.29. cfDNA and/or cfRNA in Future Companion Diagnostics

Figure 5.53. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous questions (see 5.30)

Table 5.53. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous questions (see 5.30)

Figure 5.54. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous questions (see 5.30) (Study 1)

Table 5.54. The future use of cfDNA and/or cfRNA in the development of companion diagnostics, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous questions (see 5.30) (Study 1)

CHAPTER 6 EXOSOMES

6.1. This Chapter

6.2. Current study of Exosomes

Figure 6.1. The study of exosomes by CTC cfDNA-RNA 2015 participants

Table 6.1. The study of exosomes by CTC cfDNA-RNA 2015 participants

Figure 6.2. The study of exosomes by CTC cfDNA-RNA 2015 participants (Study 1)
Table 6.2. The study of exosomes by CTC cfDNA-RNA 2015 participants (Study 1)

6.3. Future study of Exosomes

Figure 6.3. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous question, see 6.3).

Table 6.3. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous question, see 6.3).

Figure 6.4. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous question, see 6.3) (Study 1)

Table 6.4. The future study of exosomes, anticipated by CTC cfDNA-RNA 2015 participants (for those who answered 'no' to the previous question, see 6.3) (Study 1)

6.4. Disease Areas

Figure 6.5. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate

Table 6.5. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate

Figure 6.6. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate (Study 1)

Table 6.6. Disease areas of of CTC cfDNA-RNA 2015 participants, to which their exosome studies relate (Study 1)

6.5. Isolation of Exosomes

CHAPTER 7 CLINICAL TRIALS

7.1. This Chapter

7.2. Clinical Trials

Figure 7.1. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA

Table 7.1. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA

Figure 7.2. CTC or cfDNA/cfRNA Clinical Trials by Recruitment Stage

Table 7.2. CTC or cfDNA/cfRNA Clinical Trials by Recruitment Stage

7.3. CTC vs. Circulating Cell-Free Nucleic Acids (cfDNA and cfRNA)

Figure 7.3. CTCs Vs. cfDNA/cfRNA in Clinical Trials

Table 7.3. CTCs Vs. cfDNA/cfRNA in Clinical Trials

7.4 Pharma Companies Studying CTCs or cfDNA/cfRNA in Clinical Trials

Figure 7.4. Pharma Companies Progresssing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA

Table 7.4. Pharma Companies Progresssing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA

Figure 7.5. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Pharma Companies

Table 7.5. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Pharma Companies

7.5 Cancer Types

Figure 7.6. Pharma Companies Progresssing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Cancer Type

Table 7.6. Pharma Companies Progresssing Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Cancer Type

Figure 7.7. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Cancer Type

Table 7.7. CTCs Vs. cfDNA/cfRNA in Clinical Trials by Cancer Type

7.6 Approved Drugs and CTCs or cfDNA/cfRNA Clinical Trials

Figure 7.8. Approved Drugs in Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, 2012-2015

Table 7.8. Approved Drugs in Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, 2012-2015

7.7 CTC or cfDNA/cfRNA by Clinical Trial Phase

Figure 7.9. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Pharma Company and Clinical Trials Phase

Table 7.9. Clinical Trials incorporating the study of CTCs or cfDNA/cfRNA, by Pharma Company and Clinical Trials Phase

CHAPTER 8 DISCUSSION

8.1 Discussion

I would like to order

Product name: Liquid Biopsy Markets: Global Analysis and Opportunity Evaluation 2016 - 2020

Product link: <https://marketpublishers.com/r/LF5C073E6DAEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LF5C073E6DAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970